SUCCESSFUL TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA CAUSED BY MULTIDRUG RESISTANT ACINETOBACTER BAUMANNII WITH A COMBINATION THERAPY OF CSE1034 AND COLISTIN: A CASE REPORT.


Himanshu Garg, Pratibha Dogra, Mayank Saxena

Abstract


 Objective: One of the major causes of ventilator-associated pneumonia (VAP) in hospital settings is Acinetobacter baumannii. The propensity of acquiring antimicrobial resistance rapidly through a multiple number of mechanisms makes the selection of an appropriate empirical antimicrobial agent exceedingly challenging for this pathogen.

Methods: The present case report explores the option of treating VAP infection due to carbapenem-resistant pathogens with antibiotic adjuvant entities.

Results: We present a case of VAP due to carbapenem-resistant A. baumannii that was successfully treated with CSE-1034 and colistin combination therapy.

Conclusion: Early recognition and appropriate antibiotic therapy are essential to eliminate poor outcomes in multidrug-resistant (MDR) bacterial infections. The present case highlights the antibiotic adjuvant entity “CSE-1034” as an empiric option for the treatment of VAP due to MDR A. baumannii in intensive care unit.


Keywords


CSE1034, Colistin, Pneumonia, Acinetobacter baumannii, Carbapenamases.

| PDF |

References


Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:3471-84.

Arjuna A, Nandi D. Acinetobacter main cause of hospital acquired infections: A review. Asian J Pharm Clin Res 2017;10:53-6.

Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: Evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 2015;36:85-98.

Almomani B, Al-Gharaibeh R, Al-Mahasneh F, Samrah S. Multidrug resistant Acinetobacter baumannii in ventilator associated pneumonia: Prevalence and predictors of mortality. Eur Respir J 2014;44:2071.

Siegel RE. Emerging gram-negative antibiotic resistance: Daunting challenges, declining sensitivities, and dire consequences. Respir Care 2008;53:471-9.

Ganguly NK, Arora NK, Chandy SJ, Fairoze MN, Gill JP, Gupta U, et al. Rationalizing antibiotic use to limit antibiotic resistance in India. Indian J Med Res 2011;134:281-94.

Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Acinetobacter baumannii 2002-2008: Increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 2010;16:209-15.

Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin Microbiol Infect 2016;22 Suppl 1:S9-14.

Lin MF, Lan CY. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases 2014;2:787-814.

Kornum JB, Thomsen RW, Riis A, Lervang HH, Schønheyder HC, Sørensen HT. Type 2 diabetes and pneumonia outcomes: A population-based cohort study. Diabetes Care 2007;30:2251-7.

Song SW, Kim KT, Ku YM, Park SH, Kim YS, Lee DG, et al. Clinical role of interstitial pneumonia in patients with scrub typhus: A possible marker of disease severity. J Korean Med Sci 2004;19:668-73.

Chaudhary M, Mir MA, Ayub SG; Protocol Group. Safety and efficacy of a novel drug elores (ceftriaxone sulbactam disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: A post-marketing surveillance study. Braz J Infect Dis 2017;21:408-17

Chaudhary M, Payasi A. Incidence, prevalence and control of multidrug resistant (MDR) carbapenemase producing Acinetobacter baumanii in Indian intensive care units. J Pharm Res 2013;7:175-80.

Sathe P, Maddani S, Kulkarni S, Munshi N. Management of ventilator associated pneumonia with a new antibiotic adjuvant entity (ceftriaxone sulbactam disodium edetate)-a novel approach to spare carbapenems. J Crit Care 2017;41:145-9.

Chaudhary M, Payasi A. Synergy of a novel antibiotic adjuvant entity against multi drug resistant Enterobacteriaceae. Am J Infect Dis 2013;9:94-103.

Chaudhary M, Payasi A. A randomized, open-label, prospective, multicenter Phase-III clinical trial of Elores in lower respiratory tract and urinary tract infections. J Pharm Res 2013;6:409-14.

Lee CS, Doi Y. Therapy of infections due to carbapenem-resistant gram-negative pathogens. Infect Chemother 2014;46:149-64.

Lambert RJ, Hanlon GW, Denyer SP. The synergistic effect of EDTA/antimicrobial combinations on Pseudomonas aeruginosa. J Appl Microbiol 2004;96:244-53.

Singh AP, Gupta DU, Das S. Monitor the use of antibiotics in intensive care units with special focus on restricted antibiotics in tertiary care hospital of India. Asian J Pharm Clin Res 2016;9:256-9.




About this article

Title

SUCCESSFUL TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA CAUSED BY MULTIDRUG RESISTANT ACINETOBACTER BAUMANNII WITH A COMBINATION THERAPY OF CSE1034 AND COLISTIN: A CASE REPORT.

Keywords

CSE1034, Colistin, Pneumonia, Acinetobacter baumannii, Carbapenamases.

DOI

10.22159/ajpcr.2018.v11i2.21619

Date

01-02-2018

Additional Links

Manuscript Submission

Journal

Asian Journal of Pharmaceutical and Clinical Research
Vol 11 Issue 2 February 2018 Page: 1-3

Print ISSN

0974-2441

Online ISSN

2455-3891

Authors & Affiliations

Himanshu Garg
Department of Respiratory, Artemis Hospital, Noida, Uttar Pradesh, India.
India

Pratibha Dogra
Department of Respiratory, Artemis Hospital, Noida, Uttar Pradesh, India
India

Mayank Saxena
Department of Respiratory, Artemis Hospital, Noida, Uttar Pradesh, India.
India


Article Tools


Email this article (Login required)
Email the author (Login required)

Refbacks

  • There are currently no refbacks.